Ziprasidone: Efficacy, tolerability, and emerging data on wide-ranging effectiveness

Philip D Harvey, Christopher R. Bowie

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Ziprasidone is the fifth atypical antipsychotic to become available in the US market. This compound is a serotonin-dopamine-receptor antagonist, with greater affinity for the 5-HT2A receptor than the dopamine D2 receptor. Similar to aripiprazole, this compound also has agonist activity at the serotonin 5-HT1A receptor. This affinity has the potential to have particularly beneficial effects on cognitive and affective abnormalities in schizophrenia. Oral and short-acting intramuscular formulations are available. This compound has recently been approved for the treatment of acute mania as well as for schizophrenia. Ziprasidone is associated with low weight gain and a low potential to change lipid and glucose levels. Long-term tolerability data have indicated that initial concerns regarding QTc (corrected cardiac output) prolongation are not a major issue. Recent data have indicated that this compound has short-term antipsychotic efficacy that is equivalent to other members of the class, also with evidence of cognitive enhancement. Finally, longer term data has indicated that ziprasidone is successful in the prevention of relapse and has sustained cognitive benefits. Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy.

Original languageEnglish
Pages (from-to)337-346
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number2
DOIs
StatePublished - Feb 1 2005
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Receptor, Serotonin, 5-HT2A
Serotonin Antagonists
Receptor, Serotonin, 5-HT1A
Dopamine Antagonists
Dopamine D2 Receptors
Secondary Prevention
Bipolar Disorder
Cardiac Output
Weight Gain
Lipids
Glucose
Food
ziprasidone
Therapeutics
Aripiprazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ziprasidone : Efficacy, tolerability, and emerging data on wide-ranging effectiveness. / Harvey, Philip D; Bowie, Christopher R.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 2, 01.02.2005, p. 337-346.

Research output: Contribution to journalArticle

@article{af62f1d1ab384808ac8849955ac7bdfe,
title = "Ziprasidone: Efficacy, tolerability, and emerging data on wide-ranging effectiveness",
abstract = "Ziprasidone is the fifth atypical antipsychotic to become available in the US market. This compound is a serotonin-dopamine-receptor antagonist, with greater affinity for the 5-HT2A receptor than the dopamine D2 receptor. Similar to aripiprazole, this compound also has agonist activity at the serotonin 5-HT1A receptor. This affinity has the potential to have particularly beneficial effects on cognitive and affective abnormalities in schizophrenia. Oral and short-acting intramuscular formulations are available. This compound has recently been approved for the treatment of acute mania as well as for schizophrenia. Ziprasidone is associated with low weight gain and a low potential to change lipid and glucose levels. Long-term tolerability data have indicated that initial concerns regarding QTc (corrected cardiac output) prolongation are not a major issue. Recent data have indicated that this compound has short-term antipsychotic efficacy that is equivalent to other members of the class, also with evidence of cognitive enhancement. Finally, longer term data has indicated that ziprasidone is successful in the prevention of relapse and has sustained cognitive benefits. Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy.",
author = "Harvey, {Philip D} and Bowie, {Christopher R.}",
year = "2005",
month = "2",
day = "1",
doi = "10.1517/14656566.6.2.337",
language = "English",
volume = "6",
pages = "337--346",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Ziprasidone

T2 - Efficacy, tolerability, and emerging data on wide-ranging effectiveness

AU - Harvey, Philip D

AU - Bowie, Christopher R.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Ziprasidone is the fifth atypical antipsychotic to become available in the US market. This compound is a serotonin-dopamine-receptor antagonist, with greater affinity for the 5-HT2A receptor than the dopamine D2 receptor. Similar to aripiprazole, this compound also has agonist activity at the serotonin 5-HT1A receptor. This affinity has the potential to have particularly beneficial effects on cognitive and affective abnormalities in schizophrenia. Oral and short-acting intramuscular formulations are available. This compound has recently been approved for the treatment of acute mania as well as for schizophrenia. Ziprasidone is associated with low weight gain and a low potential to change lipid and glucose levels. Long-term tolerability data have indicated that initial concerns regarding QTc (corrected cardiac output) prolongation are not a major issue. Recent data have indicated that this compound has short-term antipsychotic efficacy that is equivalent to other members of the class, also with evidence of cognitive enhancement. Finally, longer term data has indicated that ziprasidone is successful in the prevention of relapse and has sustained cognitive benefits. Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy.

AB - Ziprasidone is the fifth atypical antipsychotic to become available in the US market. This compound is a serotonin-dopamine-receptor antagonist, with greater affinity for the 5-HT2A receptor than the dopamine D2 receptor. Similar to aripiprazole, this compound also has agonist activity at the serotonin 5-HT1A receptor. This affinity has the potential to have particularly beneficial effects on cognitive and affective abnormalities in schizophrenia. Oral and short-acting intramuscular formulations are available. This compound has recently been approved for the treatment of acute mania as well as for schizophrenia. Ziprasidone is associated with low weight gain and a low potential to change lipid and glucose levels. Long-term tolerability data have indicated that initial concerns regarding QTc (corrected cardiac output) prolongation are not a major issue. Recent data have indicated that this compound has short-term antipsychotic efficacy that is equivalent to other members of the class, also with evidence of cognitive enhancement. Finally, longer term data has indicated that ziprasidone is successful in the prevention of relapse and has sustained cognitive benefits. Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy.

UR - http://www.scopus.com/inward/record.url?scp=14544300071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544300071&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.2.337

DO - 10.1517/14656566.6.2.337

M3 - Article

C2 - 15757429

AN - SCOPUS:14544300071

VL - 6

SP - 337

EP - 346

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -